Pfizer, Inc. (NYSE:PFE) announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02, Morningstar.com reports. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the company posted $0.64 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Pfizer updated its FY17 guidance to $2.54-2.60 EPS.
Shares of Pfizer (PFE) opened at 32.67 on Friday. The firm’s 50-day moving average price is $33.30 and its 200 day moving average price is $33.38. Pfizer has a one year low of $29.83 and a one year high of $35.38. The company has a market capitalization of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.92%. Pfizer’s dividend payout ratio is currently 94.12%.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of PFE. Asset Planning Services Ltd. boosted its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Pfizer during the second quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer during the second quarter valued at approximately $103,000. D. Scott Neal Inc. boosted its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Finally, Orrstown Financial Services Inc. boosted its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Institutional investors own 69.94% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/19/pfizer-inc-pfe-posts-quarterly-earnings-results-beats-estimates-by-0-02-eps-updated-updated.html.
Several brokerages have commented on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. BMO Capital Markets reiterated a “hold” rating and issued a $33.00 target price on shares of Pfizer in a report on Thursday, April 27th. Sanford C. Bernstein reissued a “buy” rating and issued a $35.00 price target on shares of Pfizer in a research report on Monday, April 24th. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Finally, Barclays PLC reissued a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average target price of $37.61.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.